BioCentury
ARTICLE | Clinical News

BIL-010t: Phase I data

August 11, 2014 7:00 AM UTC

A single-arm, open-label, U.S. Phase I trial in 21 patients with a histologically confirmed BCC lesion within the previous 4 weeks showed that topical BIL-010t for 28 days was well tolerated with mild...